Bruel, Timothée

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 1,992

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W.-H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2022) · Nature

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 1,514

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Sterlin, D., Mathian, A., Miyara, M., Mohr, A., Anna, F., Claër, L., Quentric, P., Fadlallah, J., Devilliers, H., Ghillani, P., et al. (2021) · Science Translational Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 1,037

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 697

Syncytia formation by SARS‐CoV‐2‐infected cells

Buchrieser, J., Dufloo, J., Hubert, M., Monel, B., Planas, D., Rajah, M. M., Planchais, C., Porrot, F., Guivel‐Benhassine, F., Van der Werf, S., et al. (2020) · The EMBO Journal

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 462

A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

Grzelak, L., Temmam, S., Planchais, C., Demeret, C., Tondeur, L., Huon, C., Guivel-Benhassine, F., Staropoli, I., Chazal, M., Dufloo, J., et al. (2020) · Science Translational Medicine

SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testing

Cited by 310

Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection

Gallais, F., Gantner, P., Bruel, T., Velay, A., Planas, D., Wendling, M.-J., Bayer, S., Solis, M., Laugel, E., Reix, N., et al. (2021) · EBioMedicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 240

IFITM Proteins Incorporated into HIV-1 Virions Impair Viral Fusion and Spread

Compton, A. A., Bruel, T., Porrot, F., Mallet, A., Sachse, M., Euvrard, M., Liang, C., Casartelli, N., & Schwartz, O. (2014) · Cell Host & Microbe

HIV Research and Treatmentinterferon and immune responses

Cited by 231

Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France

Fafi-Kremer, S., Bruel, T., Madec, Y., Grant, R., Tondeur, L., Grzelak, L., Staropoli, I., Anna, F., Souque, P., Fernandes-Pellerin, S., et al. (2020) · eBioMedicine

SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testing

Cited by 108

Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies

Dufloo, J., Grzelak, L., Staropoli, I., Madec, Y., Tondeur, L., Anna, F., Pelleau, S., Wiedemann, A., Planchais, C., Buchrieser, J., et al. (2021) · Cell Reports Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 89

HIV-1 cell-to-cell transmission and broadly neutralizing antibodies

Dufloo, J., Bruel, T., & Schwartz, O. (2018) · Retrovirology

HIV Research and TreatmentHIV/AIDS Research and Interventions

Cited by 69